ClinicalTrials.gg
Active, not recruitingNCT05445323Updated Dec 23, 2025

Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia

A Phase 1/2 interventional study of Low dose LX2006 and Mid Dose LX2006 in Friedreich Ataxia and Cardiomyopathy, Secondary, sponsored by Lexeo Therapeutics. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Lexeo Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Friedreich Ataxia with a site in United States — 18 open to participants now, 25 under way, 4 of them phase 3. Friedreich Ataxia · United States.

Enrollment
44th of 49
8 · median 32
Started
2022
with 7 others
Phase 1/2
3 of 71
none open now
Primary completion
2029-09
later than 16 of 24 live
Registered
47th of 71
by date
Lead sponsor
3 of 71
Lexeo Therapeutics

Among the 71 studies in Friedreich Ataxia with a site in United States, this one is the 44th largest by enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2022, is one of 3 in phase 1/2, reaches primary completion later than 16 of the 24 other live ones, and was the 47th registered.

Friedreich Ataxia

111 studies on the registry are indexed under Friedreich Ataxia; 28 are open to participants now.

Browse Friedreich Ataxia studies →

Open to participants now

18 of the 71 studies in Friedreich Ataxia with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Friedreich Ataxia studies recruiting now, 9 (50%) set no upper age limit and 9 (50%) stop at 75 or younger; 15 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Friedreich Ataxia with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of LX2006 for participants who have Friedreich's Ataxia with evidence of cardiomyopathy. The study will evaluate up to three doses of single administration of LX2006 (AAVrh.10hFXN), an adeno-associated virus (AAV) gene therapy designed to intravenously deliver the human frataxin (hFXN) gene to cardiac cells over a 52-week period. Long-term safety and efficacy will be evaluated for an additional 4-years for a total of 5-years post LX2006 treatment.

Read the detailed description

Friedreich's ataxia (FA) is a rare, autosomal recessive disease caused by a mutation in the autosomal frataxin (FXN) gene. Progressive cardiomyopathy with cardiac hypertrophy and fibrosis is observed in most individuals with FA. The disease is more severe in those with earlier onset. Presently, there is no therapy that alters the progression of cardiomyopathy in FA, which is responsible for 59% of FA-related deaths.

The primary objective of this dose escalation study is to assess the safety and tolerability of three ascending doses of LX2006 in patients with FA-associated cardiomyopathy. LX2006 is designed to restore hFXN levels in order to improve mitochondrial function. Assessments of cardiac function, biomarkers and other preliminary efficacy endpoints are also included in this study.

03

Conditions studied

  • Friedreich Ataxia
  • Cardiomyopathy, Secondary

Keywords

  • Friedreich's Ataxia
  • Cardiomyopathy
  • FA
  • Gene therapy
  • FXN Gene
  • Frataxin Gene
  • LX2006
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed genetic diagnosis of FA, with onset being before 25 years of age
  • Protocol specified ranges for antibodies
  • Protocol specified measures of FA cardiomyopathy

Exclusion criteria

Exclusion Criteria:

  • Protocol specified ranges for (LVEF) as measured by cardiac ECHO
  • Uncontrolled diabetes
  • Abnormal liver function
  • Active infection of any type, including hepatitis virus (A, B or C) or (HIV-1 and HIV-2)
  • to cardiac MRI
  • Contraindications to cardiac
  • Participants who are receiving systemic or other medications
  • History of significant coronary artery disease or any structural heart or vascular disease other than FA cardiomyopathy
  • Presence of , hemodynamically unstable arrhythmias, requiring physician intervention
  • Presence of clinically significant abnormalities as determined by the investigator, other than abnormalities related to FA
  • Uncontrolled psychiatric disease

Other Inclusion/Exclusion criteria to be applied as per protocol.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1/ Cohort 2/ Cohort 3

    Genetic: Low dose LX2006 · Genetic: Mid Dose LX2006 · Genetic: High Dose LX2006

Interventions

  • GeneticLow dose LX2006

    Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

  • GeneticMid Dose LX2006

    Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

  • GeneticHigh Dose LX2006

    Adeno-associated viral vector encoding the FXN gene (AAVrh.10hFXN)

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious events (TESAEs)

    Time frame: Change from baseline to end of year 5 post dose

Secondary outcomes

  1. Change from baseline in LVMi

    Time frame: Change from baseline to end of year 5 post dose

  2. Change from baseline in LVEF

    Time frame: Change from baseline to end of year 5 post dose

  3. Change from baseline in cardiac fibrosis as measured by cardiac MRI

    Time frame: Change from baseline to end of year 5 post dose

  4. Change from baseline in measures of cardiopulmonary exercise tolerance

    Time frame: Change from baseline to end of year 5 post dose

  5. Presence and severity of cardiac arrythmias

    Time frame: Change from baseline to end of year 5 post dose

07

Study locations

3 sites
08

References and documents

Publications

  • Crystal RG, Weinsaft JW, Kaminsky SM, Caragiulo A, Savage N, Patel A, Gavrilova RH, Perlman SL, Galbraith M, Kahlon U, Krishnan U, Kaner RJ, Sanders A, Vo M, Sarva H, Yoo A, Sondhi D, De BP, Mezey JG, Aubert G, Khan A, Selvan N, Bhalla N, Adler E, Zesiewicz T. AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial. JAMA Cardiol. 2026 Jun 17:e261699. doi: 10.1001/jamacardio.2026.1699. Online ahead of print. PubMed 42307907 ↗
  • Hendrickx N, Mentre F, Hamdan A, Karlsson MO, Hooker AC, Traschutz A, Gagnon C, Schule R, Synofzik M, Comets E; ARCA Study Group, EVIDENCE-RND consortium. Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score. BMC Med Res Methodol. 2025 Jul 30;25(1):179. doi: 10.1186/s12874-025-02626-x. PubMed 40739200 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Sep 2029, 85 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2022
First posted
Jul 6, 2022
StartActual
Aug 24, 2022
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05445323
Lead sponsor
Lexeo Therapeutics
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Aug 24, 2022
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Dec 23, 2025

Study contacts

LEXEO Clinical Trials
study director · Lexeo Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion